Arya Sciences II (ARYB) to Combine with Cerevel Therapeutics

Arya Sciences II (ARYB) to Combine with Cerevel Therapeutics

Jul 30, 2020 INTEL by Kristi Marvin
Arya Sciences Acquisition Corp. II (ARYB), announced this morning that they have entered into a definitive business combination agreement with Cerevel Therapeutics, Inc. (“Cerevel Therapeutics”), a company dedicated to treating neuroscience diseases. This transaction is expected to have an initial market capitalization of approximately $1.3 billion, with an implied enterprise value of $847.4 million. In
Read More
To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.

Leave a Reply